In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Thomas J A Graham und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States. Hauptthemen laut MEDLINE: Tauopathies, Alzheimer Disease, Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
A chemical fingerprint search identified Z3777013540 (1-(5-(6-fluoro-1H-indol-2-yl)pyrimidin-2-yl)piperidin-4-ol; 1) as a potential 4R-tau binding ligand. Binding assays in post-mortem Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) brain with [3H]1 provided KD (nM) values in AD = 4.0, PSP = 5.1, and CBD = 4.5. In vivo positron emission tomography (PET) imaging in rats with [18F]1 demonstrated good brain penetration and rapid clearance from normal brain tissues. A subsequent molecular similarity search using 1 as the query revealed an additional promising compound, Z4169252340 (4-(5-(6-fluoro-1H-indol-2-yl)pyrimidin-2-yl)morpholine; 21). Binding assays with [3H]21 provided KD (nM) values in AD = 1.2, PSP = 1.6, and CBD = 1.7 and lower affinities for binding aggregated α-synuclein and amyloid-beta. PET imaging in rats with [18F]21 demonstrated a higher brain penetration than [18F]1 and rapid clearance from normal brain tissues. We anticipate that 1 and 21 will be useful for the identification of other potent novel 4R-tau radiotracers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States.
- Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8, Canada.
- Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.
- Department of Psychiatry, University of Toronto, Toronto, Ontario M5T 1R8, Canada.
ORCID-Profile: Thomas J A Graham, Jeffrey S Stehouwer, Neil Vasdev, Robert H Mach
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- National Institute of Neurological Disorders and Stroke
- Canada Foundation for Innovation
- Ontario Research Foundation
- Canada Research Chairs
- Azrieli Foundation
Zitieren
APA
Graham, T. J. A., Lindberg, A., Tong, J., Stehouwer, J. S., Vasdev, N., Mach, R. H., & Mathis, C. A. (2023). In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00775
Vancouver
Graham TJA, Lindberg A, Tong J, Stehouwer JS, Vasdev N, Mach RH, et al. In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00775
BibTeX
@article{Graham2023,
author = {Graham, Thomas J A and Lindberg, Anton and Tong, Junchao and Stehouwer, Jeffrey S and Vasdev, Neil and Mach, Robert H and Mathis, Chester A},
title = {In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00775}
}
EUVIMED